Valuation: KDventures AB

Market Cap 160M 16.4M 14.42M 13.42M 12.33M 23.15M 1.57B 23.45M 62.31M 777M 61.57M 60.25M 2.68B P/E 2024
-31.7x
P/E 2025 -0.61x
Enterprise Value 137M 14.06M 12.36M 11.5M 10.57M 19.84M 1.35B 20.1M 53.41M 666M 52.78M 51.64M 2.3B EV / Sales 2024
118x
EV / Sales 2025 56.8x
Free-Float
65.1%
Yield 2024 *
-
Yield 2025 -
1 day+0.62%
1 week+0.21%
Current month+0.21%
1 month-0.81%
3 months-13.04%
6 months-14.26%
Current year-44.15%
1 week 0.24
Extreme 0.2405
0.25
1 month 0.24
Extreme 0.24
0.27
Current year 0.2
Extreme 0.2
0.45
1 year 0.2
Extreme 0.2
1.24
3 years 0.2
Extreme 0.2
1.95
5 years 0.2
Extreme 0.2
11.24
10 years 0.2
Extreme 0.2
11.24
Manager TitleAgeSince
Chief Executive Officer 61 31/05/2017
Director of Finance/CFO 58 30/09/2022
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 33 27/11/2017
Director/Board Member 57 18/02/2021
Chairman 50 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
27/03/23 Buy

General Counsel

50,000 0.0187%
30/09/22 Buy

General Counsel

40,187 0.0150%
08/03/22 Buy

Chairman

64,001 0.0367%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%+0.21%-75.70%-85.02% 16.4M
+3.23%+6.32%-16.13%-6.00% 182B
+4.58%+4.88%-6.09%-2.14% 108B
+2.51%+4.01%+10.14%+68.97% 60.54B
-4.21%-6.94%+21.43%+48.82% 50.53B
+4.44%+5.44%-11.33%-42.13% 43.79B
+3.29%+3.45% - - 33.57B
+2.06%-0.79%-17.17%-43.98% 28.31B
-0.27%-6.75%+29.97%-8.33% 23.31B
+4.47%+5.05%-1.80%-3.30% 21.28B
Average +2.06%-0.59%-7.41%-8.12% 55.12B
Weighted average by Cap. +2.66%+0.78%-4.29%+3.79%

Financials

2024 2025
Net sales 1.84M 189K 166K 155K 142K 267K 18.12M 270K 718K 8.95M 709K 694K 30.93M 1.67M 172K 151K 141K 129K 242K 16.47M 246K 653K 8.13M 645K 631K 28.12M
Net income -8.1M -833K -732K -682K -626K -1.18M -79.87M -1.19M -3.16M -39.44M -3.13M -3.06M -136M -194M -19.93M -17.52M -16.31M -14.98M -28.12M -1.91B -28.5M -75.71M -944M -74.81M -73.2M -3.26B
Net Debt -39.9M -4.1M -3.61M -3.36M -3.08M -5.79M -393M -5.86M -15.58M -194M -15.4M -15.07M -671M -22.8M -2.34M -2.06M -1.92M -1.76M -3.31M -225M -3.35M -8.9M -111M -8.8M -8.61M -384M
Logo KDventures AB
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Employees
7
Date Price Change Volume
28/07/26 SEK 0.2435 +0.62% 201,178
27/07/26 SEK 0.2420 -1.83% 151,494
24/07/26 SEK 0.2465 -0.20% 325,289
23/07/26 SEK 0.2470 +0.41% 351,628
22/07/26 SEK 0.2460 +1.23% 277,735

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KDV B Stock